Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

  title={Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.},
  author={Junia V. Melo and Charles T. H. Chuah},
  journal={Hematology. American Society of Hematology. Education Program},
The emergence of resistance to imatinib has become a significant problem despite the remarkable clinical results achieved with this tyrosine kinase inhibitor in the treatment of chronic myeloid leukaemia. The most common cause of imatinib resistance is the selection of leukemic clones with point mutations in the Abl kinase domain. These mutations lead to amino acid substitutions and prevent the appropriate binding of imatinib. Genomic amplification of BCR-ABL, modulation of drug efflux or… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 24 extracted citations


Publications referenced by this paper.
Showing 1-10 of 81 references

Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL [abstract

C Gambacorti-Passerini, HM Kantarjian, M Baccarani
J Clin Oncol • 2008

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors [abstract

TH Brummendorf, F Cervantes, D Kim
J Clin Oncol • 2008

Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase II study [abstract

P le Coutre, FJ Giles, J Apperley
J Clin Oncol • 2008

Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract

FJ Giles, RA Larson, HM Kantarjian
J Clin Oncol • 2008

Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results [abstract

HM Kantarjian, FJ Giles, A Hochhaus
J Clin Oncol • 2008

Similar Papers

Loading similar papers…